Previous studies have showed that patients with B-ALL or B cell lymphoma receiving CAR-T therapy targeting CD19 or CD22, and experiencing ICANS refractory to systemic steroids can gain favorable outcomes after intrathecal corticosteroids or chemotherapy (17–19). Here, CD19 is linked to B-cell non-Hodgkin lymphoma.